Do CSF levels of t-Tau, p-Tau and β1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 11, 2014, Pages 2137-2143

  Chiaravalloti, Agostino ^a   Stefani, Alessandro ^a,b   Fiorentini, Alessandro ^a   Lacanfora, Annamaria ^a   Stanzione, Paolo ^a   Schillaci, Orazio ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

Amyloid; DaTscan; p Tau; Parkinson disease; t Tau

Indexed keywords

2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; DOPAMINE; PEPTIDE FRAGMENT; TAU PROTEIN; TROPANE DERIVATIVE;

AGED; CEREBROSPINAL FLUID; DIAGNOSTIC USE; FEMALE; HUMAN; MALE; METABOLISM; PARKINSON DISEASE; PHOSPHORYLATION; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DOPAMINE; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84930978114     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2841-4     Document Type: Article

References (33)

1. Schillaci O, Chiaravalloti A, Pierantozzi M, Di Pietro B, Koch G, Bruni C, et al. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson’s disease at the early stages: molecular imaging with 123I-FP-CIT SPECT. Int J Mol Med. 2011;28:881–6.
2. Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia. J Neurol Neurosurg Psychiatry. 2013;84:774–83.
3. Chiaravalloti A, Stefani A, Di Biagio D, Pierantozzi M, Tavolozza M, Di Pietro B, et al. Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson’s disease. Ann Nucl Med. 2013;27:444–51.
4. Halliday G, Lees A, Stern M. Milestones in Parkinson’s disease – clinical and pathologic features. Mov Disord. 2011;26:1015–21.
5. Playford ED, Brooks DJ. In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovasc Brain Metab Rev. 1992;4:144–71.
6. Treglia G, Cason E, Cortelli P, Gabellini A, Liguori R, Bagnato A, et al. Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques? J Neuroimaging. 2014;24:149–54.
7. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement. 2014. doi:10.1016/j.jalz.2014.02.004.
8. Tamaoka A, Sawamura N, Odaka A, Suzuki N, Mizusawa H, Shoji S, et al. Amyloid beta protein 1-42/43 (A beta 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study. Brain Res. 1995;679:151–6.
9. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, Bush AI. Tau protein: relevance to Parkinson’s disease. Int J Biochem Cell Biol. 2010;42:1775–8.
10. Medina M, Avila J. The role of extracellular Tau in the spreading of neurofibrillary pathology. Front Cell Neurosci. 2014;8:113.
11. Consensus report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998;19:109–16.
12. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013;70:1277–87.
13. Attems J, Quass M, Jellinger KA. Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. Acta Neuropathol. 2007;113:53–62.
14. Hughes A, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;66:181–4.
15. Fahn S, Elton RL, Committee motUD. Unified Parkinson’s disease rating scale. Florhan Park HJ: Macmillan Healthcare Information; 1987
16. Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, et al. Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int. 2011;2011:246412.
17. Dickson JC, Tossici-Bolt L, Sera T, de Nijs R, Booij J, Bagnara MC, et al. Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging. 2012;39:188–97.
18. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using 123I-labelled dopamine transporter ligands. Eur J Nucl Med Mol Imaging. 2002;29:BP30–5.
19. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978:25:638–43.
20. Schillaci O, Chiaravalloti A, Travascio L, Floris R, Simonetti G. F-FDG PET/MR in herpes simplex virus encephalitis: A case study. Rev Esp Med Nucl Imagen Mol. 2014. doi:10.1016/j.remn.2013.10.002.
21. Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with (123)I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2005;32:1452–6.
22. Chiaravalloti A, Danieli R, Abbatiello P, Di Pietro B, Travascio L, Cantonetti M, et al. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1123–32.
23. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev Camb Philos Soc. 2007;82:591–605.
24. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
25. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease. Neurobiol Aging. 2007;28:742–7.
26. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, et al. CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord. 2010;25:2682–5.
27. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69:570–80.
28. Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Ueda K, et al. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson’s disease and in dementia with Lewy bodies. Brain Res. 1999;843:53–61.
29. Muntane G, Dalfo E, Martinez A, Ferrer I. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related alpha-synucleinopathies. Neuroscience. 2008;152:913–23.
30. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–44.
31. Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2013;84:1288–95.
32. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain. 2010;133:713–26.
33. Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129:526–9.